Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck Receives Positive EU CHMP Opinion for WELIREG® in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component Following Treatment With an Anti-PD-1/PD-L1 Therapy
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis and Stage 2-3 Fibrosis
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
KEYTRUDA® as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient Tumors Compared to Chemotherapy
Sacituzumab Tirumotecan Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
European Commission Approves KEYTRUDA® Plus Padcev® as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site Pathway, in Adults with Diabetic Macular Edema at AAO 2026
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa
Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver
Triumph Gold Announces Strategic Review of Non-Core Exploration Projects and $15 Million Private Placement
